Adequate lowering of blood pressure reduces the risk of hypertension-induced cardiovascular events. Worldwide, blood pressure is not optimally controlled and more effective management is needed. The efficacy and tolerability of angiotensin II type 1 receptor blockers (ARBs) have led to their widespread use. Calcium channel blockers (CCBs) are highly effective antihypertensives and amlodipine has a long half-life in the circulation. The combination of an ARB with a CCB as a single-pill, fixed-dose treatment is emerging as possibly the best therapy for preventing cardiovascular disease. Although many kinds of ARB are used in such combinations, amlodipine is mainly used as the CCB. Thus, differences in safety and efficacy among single-pill ARB/CCBs depend mainly on the ARB. Not all ARBs have the same effects and some of these may be molecular (or differential) rather than class (or common) effects. This review discusses the safety and efficacy of ARB/CCB combination therapy, with particular focus on a single-pill, fixed-dose combination of valsartan/amlodipine.
Introduction
Current guidelines for the management of hypertension recommend a target blood pressure of 140/90 mmHg, with a stricter target for patients who have a high risk of cardiovascular events (< 130/80 mmHg). 1, 2 Most hypertensive patients require two or more antihypertensive agents to reach their target blood pressure. Combination therapy is recommended to prevent the development or progression of organ damage. 1, 2 Currently available single-pill, fixed-dose combination therapies include an angiotensin II (Ang II) type 1 (AT 1 ) receptor blocker (ARB) combined S Miura, K Saku ARB/CCB combination therapy for hypertension with a calcium channel blocker (CCB) and an ARB combined with a thiazide diuretic, 3 both of which give better treatment adherence and cost savings than the component drugs given in monotherapy.
The ARBs and CCBs are effective antihypertensive agents with complementary mechanisms of action, and ARB/CCB single-pill, fixed-dose combination therapy is emerging as a rational treatment option. The CCB used in ARB/CCB single-pill, fixed-dose combinations is mainly amlodipine, whereas many different ARBs are used in these combinations. 2 Consequently, differences in the effects of single-pill ARB/CCB combinations are more likely to be due to the ARB used than to the CCB. Recent studies have indicated that not all ARBs have the same effects and that some benefits conferred by ARBs may not be class (or common) effects but, rather, molecular (or differential) effects. 4 This review discusses the safety and efficacy of ARB/CCB therapy, with particular focus on the single-pill, fixed-dose combination of valsartan/ amlodipine.
Role of the ARB in ARB/ CCB combination therapy
Single-pill fixed-dose ARB/CCB combinations contain various ARBs, such as valsartan, olmesartan, telmisartan and candesartan. ARBs block vasoconstriction and aldosterone secretion through selective blockade of the binding of Ang II to the AT 1 receptor. The principal indications for ARB treatment are shown in Table 1 ; they include hypertension in combination with myocardial infarction, atrial fibrillation, heart failure and metabolic syndrome. The effective prevention of cardiovascular events by ARBs is well established. 2 It was once thought that all ARBs had similar effects in lowering blood pressure and inhibiting myocardial hypertrophy, but differences have emerged regarding their efficacy in lowering blood pressure. 5, 6 Not all ARBs have the same effects and some benefits may be molecular rather than class-specific. 7 Differences in the efficacies of ARBs (with the exception of their ability to lower blood pressure) have been revealed by clinical trials, 8 as shown in Table 2 . For example, valsartan is more effective than 
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losartan in reducing left ventricular mass index in hypertensive patients 9 and olmesartan is more effective than candesartan. 10 These studies indicate that ARBs have varying effects on left ventricular mass index. In addition, a multicentre, randomized trial found a significant reduction in left ventricular mass index in patients treated with valsartan compared with amlodipine-treated patients. 11 The ARBs have unique molecular effects, including inverse agonism and peroxisome proliferator-activated receptor-γ stimulation. 4 The molecular structures of most ARBs are similar, including imidazole and biphenyl tetrazole groups (Fig. 1) , and the molecular effects may be due to small differences in these structures. ARBs have been found to bind to the AT 1 receptor in a unique manner. 12 -16 Since olmesartan contains a hydroxyl group in addition to an α-carboxyl group, the interactions between the hydroxyl group and Tyr 113 and between the carboxyl group and His 256 in the AT 1 receptor are essential for the potent inverse agonism of olmesartan. 13 These two interactions have been termed the 'double-chain domain'. 12 A phenyl group at Tyr 113 in the AT 1 receptor and the cyclopentyl group of irbesartan form a stronger hydrophobic interaction than the losartan-AT 1 receptor interaction. 16 Lys 199 and Ser 109 in the AT 1 receptor bind to the tetrazole and phenyl groups of valsartan ( Fig. 2 , blue colour). 14 Lys 199 binds to the tetrazole group by an ionic hydrogen bond and to the phenyl group by cation-π interaction. Ser 105 is a candidate for binding to the α-carboxyl group of valsartan. Since the unique manner in which valsartan binds to the AT 1 receptor forms a structure that looks like a letter X, we refer to this interaction as the 'X-hold' (Fig. 2B ). This unique manner of binding is important for the inverse agonism of valsartan. 14 Valsartan was found to bind to the AT 1 wildtype receptor with 32 000-fold greater selectivity compared with the AT 2 wild-type receptor (dissociation constants [k d ] of AT 1 wild-type and AT 2 wild-type receptors were 7.25 nM and 234 µM, respectively; Miura S and Saku K, unpublished). Since the k d of valsartan with respect to the AT 1 -S105A/A109A/K199Q mutant receptor which disrupts the unique 'X-hold' binding was 84 nM, selectivity was decreased by 2800-fold. Thus, the unique 'X-hold' binding may also be important for selectivity of the AT 1 receptor. The different effects of individual single-pill ARB/CCB combinations may be due to the unique Further randomized direct comparisons in large-scale clinical trials are required to confirm the clinical significance of these findings.
Valsartan can control blood pressure for 24 h, 17 probably because of its highly selective blockade of the AT 1 receptor. In addition, when the AT 1 receptor is blocked by an ARB and unbound Ang II can bind the AT 2 receptor, the stimulation of the AT 2 receptor may be involved in the effects of the ARB. The stimulation of AT 2 receptors mediates natriuresis, which may contribute to the antihypertensive effect. 18 Interestingly, the local application of valsartan by means of valsartan-eluting stents inhibits neointima formation and increases AT 2 receptor mRNA expression after vascular injury in a rabbit model, suggesting that up-regulation of the AT 2 receptor by valsartan plays an important role through its antiproliferative effect. 19 The ability to influence the AT 2 receptor may be a molecular effect of valsartan. 
Role of the CCB in ARB/ CCB combination therapy
The CCBs inhibit calcium influx through the L-type calcium channels of vascular smooth muscle. They also have significant blood pressure lowering effects and prevent cardiovascular events. 20 Indications for the use of CCBs include hypertension together with angina pectoris, left ventricular hypertrophy and carotid/coronary atherosclerosis ( Table 1 ). The CCB in most single-pill, fixed-dose ARB/CCB combinations is amlodipine, which has a long half-life of 30 -50 h. 21
Rationale for ARB/CCB combination therapy
Combination ARB/CCB therapy provides enhanced blood pressure lowering efficacy compared with the effect of ARBs or CCBs as monotherapies and may promote a counterregulatory response. 2 Activation of the sympathetic nervous system by CCB-induced vasodilation is diminished by blockade of the renin-angiotensin-aldosterone system (RAAS) with an ARB. CCB-induced RAAS activation is also blocked by ARBs. The antihypertensive effect of the ARB/CCB combination may be not only additive, but also synergistic. ARBs reduce the risk of type 2 diabetes, 22 whereas CCBs are metabolically neutral. Combination ARB/CCB therapy may also help to reduce the adverse events associated with CCBs. For example, Philipp et al. 23 reported that peripheral oedema was present in 5.4% of hypertensive patients treated with valsartan/amlodipine compared with 8.7% under amlodipine monotherapy. In contrast to ARBs, amlodipine is not recommended as a firstline treatment in hypertensive patients with proteinuric renal disease. 24 ARBs can overcome the disadvantages of amlodipine in ARB/CCB combination therapy.
Therapeutic safety and efficacy of valsartan or amlodipine monotherapy
Treatment of hypertension with valsartan or amlodipine monotherapy has been shown to have a good safety profile and to be effective. Valsartan reduces both systolic and diastolic blood pressure in a dose-dependent manner 
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in the range of 80 -320 mg/day; doses as high as 640 mg/day have been demonstrated to have good safety and to be effective. 25 Large-scale clinical trials have shown that valsartan reduces cardiovascular events. 26 -30 In two randomized trials of highrisk Japanese patients with hypertension, 29, 30 treatment with valsartan resulted in fewer fatal and non-fatal cardiovascular events than non-ARB treatment. There were no differences in mortality or tolerability between the groups. 29 These reports indicated that valsartan-based therapy has a protective effect on the cardiovascular system.
Amlodipine monotherapy (2.5 -10 mg/day) is an effective antihypertensive treatment in patients with mild to moderate hypertension and has efficacy and tolerability profiles similar to those of other conventional antihypertensive drugs. 20
Therapeutic safety and efficacy of valsartan/ amlodipine combination therapy
Single-pill, fixed-dose combination amlodipine/valsartan therapy is available in the USA, Japan and several countries in Europe for once-daily oral administration in patients with hypertension and has been approved by the US Food and Drug Administration as an initial or first-line therapy in patients who are likely to need multiple drugs to achieve their target blood pressure.
Combination therapy with valsartan and amlodipine has been shown to be effective, well tolerated and to have a good safety profile for the treatment of hypertension that is not well controlled by valsartan monotherapy. 31 Several randomized and/or double-blind studies have examined the safety and efficacy of valsartan/amlodipine combination therapy and these are summarized in Table 3 . 32 -36 Combination treatment with valsartan/amlodipine (160/ 5 -10 mg/day) or lisinopril/hydrochorothiazide (10 -20/12.5 mg/day) was well tolerated and effective, both treatments resulting in the achievement of blood pressure targets in adults with stage 2 hypertension. 32 In patients with hypertension that was not controlled by monotherapy, 16 weeks' treatment with valsartan/amlodipine at 160/5 or 160/10 mg/day controlled blood pressure in 72.7% and 74.8% of patients, respectively. 33 Treatment with valsartan/amlodipine was associated with significantly greater reductions in blood pressure than valsartan or amlodipine monotherapy in patients with mild to moderate hypertension. 23 Combination therapy with 160/5 mg/day valsartan/amlodipine reduced systolic blood pressure and controlled overall blood pressure more effectively than amlodipine 10 mg/day. 34 Valsartan/amlodipine combination therapy was compared with amlodipine or valsartan monotherapy in two large randomized, double-blind, placebo-controlled studies and was associated with greater blood pressure lowering effects than each monotherapy and placebo, and the combination regimens were well tolerated. 37 In a further study, patients treated with 160/5 -10 mg/day valsartan/amlodipine had significantly greater reductions in systolic blood pressure than those receiving 5 -10 mg/day amlodipine alone. 35 These reductions were significantly greater in patients in the following subgroups: ≥ 65 years old; patients with isolated systolic hypertension; patients with body mass index ≥ 30 kg/m 2 ; patients with type 2 diabetes; and Caucasian or Hispanic patients.
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A study of Black patients with stage 2 hypertension revealed greater and more rapid reductions in blood pressure and significantly higher blood pressure control rates with valsartan/amlodipine compared with amlodipine monotherapy. 36 An openlabel, single-arm trial evaluating the efficacy and tolerability of valsartan/amlodipine in patients who were not adequately responding to treatment with amlodipine or felodipine alone found a clinically and statistically significant additional reduction in systolic blood pressure. 38 In that study, > 50% of patients treated with 160/5 mg/day valsartan/amlodipine achieved target blood pressure levels, with a low rate of adverse events.
Combination therapy with valsartan/ amlodipine is a rational and convenient treatment option for the management of patients with hypertension. Single-pill, fixeddose combination therapy with these agents is well tolerated and cost-effective, and is associated with fewer drug discontinuations, clinic visits, laboratory tests and electrocardiograms compared with conventional treatments. 39 The total cost of single-pill, fixed-dose combination therapy is generally accepted as significantly less than the cost of using the individual drug components.
Although several trials have been designed to test the antihypertensive efficacy of the valsartan/amlodipine combination, very few studies have examined its cardiovascular or renal protective effects. Further studies are needed in this regard.
Conclusions
The valsartan/amlodipine combination is well tolerated and associated with greater absolute blood pressure reductions than monotherapy with these agents. The singlepill, fixed-dose combination results in fewer antihypertensive drug discontinuations and the cost of the combined treatment is less than that of the individual drugs. 35 Multicentre, randomized, double-blind VAL/AML 160/5 -10 -32.0/-12.5 (EX-EFFeCTS AML 5 -10 -26.4/-8.6 study) Flack et al. 36 Prospective, double-blind, parallel VAL/AML 160 -320/5 -10 -36.8/-16.1 (EX-STAND group AML 5 -10 -30.7/-12.8 study)
Studies were retrieved using the PubMed database (http://www.ncbi.nlm.nih.gov/pubmed). a Systolic/diastolic blood pressure. VAL, valsartan; AML, amlodipine; LIS, lisinopril; HCTZ, hydrochlorothiazide.
